deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT03077165

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

A 10-week Randomized, Double-blind, Placebo-controlled, Prospective, International, Multicentre, Phase IIa Study of S42909 on Leg Ulcer Healing.

Sponsor: Ilkos Therapeutic Inc.

Conditions Venous Leg Ulcer
Interventions Placebo Oral Tablet S42909 100 mg S42909 1200 mg S42909 200 mg S42909 400 mg S42909 800 mg
Updated 20 times since 2017 Last updated: Sep 14, 2020 Started: Sep 12, 2017 Primary completion: Dec 12, 2019 Completion: Jan 22, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03077165, this PHASE2 trial focuses on Venous Leg Ulcer and remains completed. Sponsored by Ilkos Therapeutic Inc., it has been updated 20 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2017 – ~Sep 2017 · 5 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Sep 2019 · 10 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Nov 2020 · 8 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Mar 2020 — Nov 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  6. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  7. Nov 2018 — Sep 2019 [monthly]

    Recruiting PHASE2

  8. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  9. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  10. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  12. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  13. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  14. Sep 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Apr 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ilkos Therapeutic Inc.
Data source: Ilkos Therapeutic Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Avellino, Italy , Avilés, Spain , Barcelona, Spain , Bardejov, Slovakia , Bassano del Grappa, Italy , Belleville, United States , Bialystok, Poland , Boise, United States , Botucatu, Brazil , Bratislava, Slovakia and 59 more locations